Introduction
mCRPC
METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Up to approximately 30% of patients with metastatic castration-resistant prostate cancer (mCRPC) harbor alterations in genes associated with homologous recombination repair (HRR), rendering them susceptible to poly (adenosine diphosphate-ribose) polymerase (PARP) inhibition.